Where's big pharma's next mega paycheck?

Axios explains that many drugs will come off patent protection in the next 6 years and biotech companies will be looking to specialized treatments as their next cash generator.

I had Gemini look at this. As I suspected, drugs for a large population may also lead the charge. I think Axios partially missed the boat. Generally speaking, the globe is aging rapidly (larger share of the population over 60) and that's an op for big pharma.

Over the next 10 to 20 years, pharmaceutical R&D and commercial strategies are being reshaped by aging global populations, breakthroughs in molecular biology, and shifting regulatory incentives.

Pharma capital is flowing toward high-margin, high-unmet-need areas, supported by platform technologies that allow precision targeting.

1. The Most Profitable Therapeutic Areas

A. Metabolic Diseases & Obesity (The Incretin Boom)

• The Opportunity: The emergence of GLP-1, GIP, and glucagon receptor agonists (such as semaglutide, tirzepatide, and next-generation triple agonists like retatrutide) has opened what is projected to be one of the largest drug markets in pharmaceutical history.

• Why It’s Profitable: Unlike traditional acute treatments, metabolic therapies are typically taken chronically over years or decades. Furthermore, these molecules are expanding indications into adjacent, highly reimbursable conditions: MASH/NASH (metabolic dysfunction-associated steatohepatitis), heart failure, chronic kidney disease, and obstructive sleep apnea.

• Next Wave: Transitioning from weekly self-injections to once-daily oral small-molecule pills, next-generation amylin analogs, and therapies designed to preserve lean muscle mass during rapid weight loss.

B. Oncology (Precision & Combination Cancer Care)

• The Opportunity: Oncology remains the single largest spending category for global biopharma. Cancer biology allows for segmented, biomarker-driven clinical trials with faster regulatory pathways (accelerated approvals).

• Why It’s Profitable: High pricing power and standard-of-care reliance on combination therapies (e.g., pairing a novel drug with an established checkpoint inhibitor), allowing companies to capture multiple revenue streams per patient.

• Next Wave: Tumor-agnostic drugs that treat specific genetic mutations regardless of organ origin, personalized neoantigen cancer vaccines, and therapies aimed at overcoming drug resistance.

C. Immunology & Autoimmune Diseases

• The Opportunity: Chronic autoimmune conditions—such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, and atopic dermatitis—require indefinite therapy.

• Why It’s Profitable: With first-generation blockbusters facing patent expirations, pharma has pivoted to more selective, better-tolerated mechanisms: IL-17, IL-23, TYK2, and dual-action biologics.

• Next Wave: Adapting oncology modalities (such as CD19 CAR-T cell therapies and bispecific T-cell engagers) to induce long-term drug-free remission in severe autoimmune diseases like lupus, systemic sclerosis, and myasthenia gravis.

D. Neurodegenerative & Central Nervous System (CNS) Disorders

• The Opportunity: Aging demographics in North America, Europe, and East Asia have turned diseases like Alzheimer’s, Parkinson’s, and ALS into urgent societal challenges.

• Why It’s Profitable: A disease-modifying therapy for a widespread condition like Alzheimer’s has immediate multi-billion-dollar potential.

• Next Wave: Moving beyond the first-generation amyloid-targeting monoclonals to tau-clearing antibodies, neuroinflammation inhibitors, and blood-brain barrier transport vehicles (shuttles that hitchhike on transferrin receptors to deliver drugs deep into brain tissue).

E. Rare & Orphan Diseases

• The Opportunity: Genetic disorders affecting small patient populations (fewer than 200,000 individuals in the U.S.).

• Why It’s Profitable: Favorable regulatory frameworks (e.g., the U.S. Orphan Drug Act) provide tax credits, fee waivers, and guaranteed market exclusivity. Because treatment options are often non-existent, payers regularly approve pricing ranging from $300,000 to over $2,000,000 annually per patient.

2. Major Drug Modalities Dominating Development

The pharmaceutical industry is migrating away from simple synthetic chemicals ("small-molecule pills") toward complex biological and genetic architectures:

Drug Class / Modality	How It Works	Key Applications
Antibody-Drug Conjugates (ADCs)	"Smart bombs" connecting a cancer-targeting antibody directly to a lethal chemotherapy payload via a chemical linker.	Solid tumors (breast, lung, bladder cancer), replacing broad-spectrum chemotherapy.
Bispecific / Multispecific Antibodies	Engineered antibodies that bind two or more targets simultaneously (e.g., pulling a cytotoxic T-cell directly to a tumor cell).	Hematologic cancers, solid tumors, and ophthalmic conditions (macular degeneration).
Targeted Protein Degraders (PROTACs & Molecular Glues)	Small molecules that recruit the cell's natural garbage disposal system (ubiquitin-proteasome) to destroy disease-causing proteins.	Targeting previously "undruggable" transcription factors and resistant cancer enzymes.
siRNA & RNA Interference (RNAi)	Molecules that silence specific genes upstream before problematic proteins can be produced.	Rare metabolic diseases, hyperlipidemia, and hypertension (with dosing as infrequent as once every 6 months).
In Vivo Gene Editing & mRNA	Using lipid nanoparticles (LNPs) to deliver CRISPR/Cas, base editors, or mRNA directly to target organs (like the liver or lungs) without removing patient cells.	Sickle cell disease, rare monogenic enzymopathies, in vivo CAR-T, and customized mRNA therapeutic vaccines.
Radioligand Therapies (RLTs)	Precision targeting molecules paired with a radioactive isotope that emits localized cellular radiation upon binding.	Prostate cancer, neuroendocrine tumors, and expanding to breast and lung cancers.

3. Structural Drivers Behind Pharma’s Focus

1. Chronic vs. One-Time Treatments: While curative gene therapies command high headlines and single-dose price tags ($3M+), continuous maintenance therapies (like metabolic or immunological injectables) generate more predictable, annuity-like revenue streams that Wall Street favors.

2. Regulatory & Policy Shifts: In the United States, policies like the Inflation Reduction Act (IRA) subject small-molecule drugs to Medicare price negotiation 9 years post-approval, compared to 13 years for large-molecule biologics. This 4-year gap has caused many major pharmaceutical companies to tilt R&D budgets disproportionately toward biologics, cell therapies, and complex conjugates.

3. AI-Enabled De Novo Design: Rather than screening millions of random chemicals, generative AI and structural biology models (e.g., protein folding and molecular docking) are accelerating early lead discovery, reducing the time required to design high-affinity binders for hard-to-reach pockets.

Pharma's next cash cows could be specialized treatments

Adriel Bettelheim, Axios News

Nov 2, 2026

Pharmaceutical companies facing a steep patent cliff are concluding the key to future profits may be customized treatments tailored to patients' genes and lifestyles — not blockbusters aimed at large patient populations.

Why it matters: The pivot could influence which diseases get treated in the decades to come, and how much the health system pays.

The stakes are huge. More than $500 billion in brand-name drug sales is potentially at risk from generic competition between 2026 and 2032, according to the consulting firm Evaluate.

The latest: The race is on to find new treatments that each generate at least $2.4 billion in global sales, a new Iqvia Institute report finds.

They're increasingly specialty treatments, biologics and rare disease drugs — with a small group of flagship products accounting for an outsized share of industry sales.

GLP-1 drugs like Novo Nordisk's Ozempic and Eli Lilly's Zepbound now define that elite category. The next wave could include "biological missiles" that combine antibodies with chemotherapy to target specific cancer cells.

"As precision medicine continues to advance, similar approaches may extend beyond oncology into areas such as immunology, metabolic disease and neurology," the report states.

Reality check: It's not clear whether all of the innovation will cure more people, or just make health care more expensive.

Novel RNA drugs and cell and gene therapies are expensive, hard to make and target small groups of patients.

Challenges identifying eligible patients and getting insurers to pay for treatments have already revealed a disconnect between promising R&D and patient benefit.

Widespread concern over high drug prices will force manufacturers to find more unmet needs and build sales more quickly after a drug's launch, according to the report.

Context: Top-selling drugs historically were aimed at large patient populations with chronic conditions like high cholesterol. The ulcer drug Tagamet became the first to exceed $1 billion in sales in 1986.

Over time, cancer and immunology drugs became major drivers of growth, followed by GLP-1s, which are sparking huge demand for conditions beyond obesity and diabetes but also driving up health costs.

Iqvia found that blockbusters on average maintain a dominant market position for 12.1 years before losing market exclusivity, or nearly 80% of their commercial life. Specialty drugs for rare or complex diseases lasted even longer.

Yes, but: A substantial number of top-sellers will lose patent protection and face potential competition from generics between 2028 and 2036.

Bristol Myers Squibb's blood thinner Eliquis and Merck's cancer blockbuster Keytruda, which are both due to lose market exclusivity in 2028, accounted for a combined $65 billion in global sales in 2024.

Follow the money: The search for new blockbusters is playing out in a highly charged environment. Drugmakers and biotechs not only have to figure out how to grow outside of crowded categories but also how much payers value new classes of drugs, Evaluate says.

There's also uncertainty over China, where Western drug giants have invested tens of billions of dollars to bolster their product pipelines.

Evaluate predicts that only autoimmune disease drugs will come close to rivaling GLP-1s, because of their potential to treat dozens of conditions.

One example is AbbVie's injectable Skyrizi for plaque psoriasis, arthritis, Crohn's disease and ulcerative colitis, which could find more uses and generate more than $33 billion in sales in 2032.

Iqvia identifies RNA therapeutics as a potentially important middle ground between traditional "small molecule" drugs for chronic diseases and highly specialized genetic treatments.

These drugs can target disease-causing mutations across many genes and conditions, with applications for central nervous system, cardiovascular and kidney disease, as well as rare conditions.

The bottom line: The success at innovating while also making sure patients have access to the new treatments "will ultimately determine whether the growth in blockbuster medicines observed over the past 25 years can continue at its extraordinary pace," Iqvia concludes.